A placebo-controlled, double-blind trial of DFO in early-stage PD showed reduced iron accumulation in the SN and delayed motor symptom progression (271)
Current projections suggest that, without effective intervention, nearly two-thirds of adults over 25 years of age could be affected by 2050, corresponding to approximately 3.8 billion individuals [1]
Circulating monocytes have been reported to promote and predict IPF progression 33,34
Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis
Its lightweight texture makes it ideal for daily outdoor exposure without feeling heavy on the skin
Haigis MC, Mostoslavsky R, Haigis KM, Fahie K, Christodoulou DC, Murphy AJ, Valenzuela DM, Yancopoulos GD, Karow M, Blander G, Wolberger C, Prolla TA, Weindruch R, Alt FW, Guarente L